CYPHERPUNK TECHNOLOGIES INC. Increase (Decrease) in Contract with Customer, Liability
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Increase (Decrease) in Contract with Customer, Liability of -$1.50 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-03-24
- CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in contract with customer, liability for the quarter ending 2021-12-31 was -$375.00K.
- CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in contract with customer, liability for the quarter ending 2021-09-30 was -$375.00K.
- CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in contract with customer, liability for the quarter ending 2021-06-30 was -$375.00K.
- CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in contract with customer, liability for the quarter ending 2021-03-31 was -$375.00K, a 114.29% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in contract with customer, liability for fiscal 2021 was -$1.50M, a 200.00% decline from fiscal 2020.
- CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in contract with customer, liability for fiscal 2020 was $1.50M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$750.00K derived: sum of 2 quarters · filed 2023-03-24 | -$1.13M derived: sum of 3 quarters · filed 2023-03-24 | -$1.50M 10-K · filed 2023-03-24 |
| 2021-09-30 | -$375.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$750.00K derived: sum of 2 quarters · filed 2022-11-14 | -$1.13M 10-Q · filed 2022-11-14 | -$1.50M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$375.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$750.00K 10-Q · filed 2022-08-12 | -$1.13M derived: sum of 3 quarters · filed 2022-08-12 | -$1.50M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$375.00K 10-Q · filed 2022-05-13 | -$750.00K derived: sum of 2 quarters · filed 2022-05-13 | -$1.13M derived: sum of 3 quarters · filed 2022-05-13 | -$1.50M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$750.00K derived: sum of 2 quarters · filed 2022-03-11 | -$1.13M derived: sum of 3 quarters · filed 2022-03-11 | $1.50M 10-K · filed 2022-03-11 |
| 2020-09-30 | -$375.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$750.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.88M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$375.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $2.25M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $2.63M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |